



Short communication

Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study

Vanessa Legry^a, Szilvia Bokor^a, Laurent Beghin^{b,c}, Myriam Galfo^d, Marcela Gonzalez-Gross^e, Denes Molnar^f, Luis A. Moreno^g, Philippe Amouyel^a, Jean Dallongeville^a, Aline Meirhaeghe^{a,*}, on behalf of the HELENA Study Group¹

^a INSERM, U744; Institut Pasteur de Lille; Univ. Lille Nord de France; UDSL, Lille, France

^b U995-Inserm, Université Lille Nord de France et CHRU de Lille, Faculté de Médecine, Lille, France

^c CIC-9301-CH&U-Inserm de Lille, IFR 114, IMPRT, CHRU de Lille, Lille, France

^d INRAN - National Research Institute for Food and Nutrition, Rome, Italy

^e Department of Health and Human Performance, Facultad de Ciencias de la Actividad Física y del Deporte - INEF, Universidad Politécnica de Madrid, Madrid, Spain

^f University of Pécs, Department of Pediatrics, Pécs, Hungary

^g "Growth, Exercise, Nutrition and Development" (GENUD) Research Group. Escuela Universitaria de Ciencias de la Salud, Universidad de Zaragoza, Zaragoza, Spain

ARTICLE INFO

Article history:

Received 28 October 2010

Received in revised form 3 January 2011

Accepted 17 January 2011

Available online 26 January 2011

Keywords:

HDL-cholesterol

Lipid

LXR alpha

ABCA1

Polymorphism

Association study

Adolescents

ABSTRACT

Objective: Genetic variability in the *NR1H3* gene (encoding LXR α) and in several of its target genes is associated with serum HDL-cholesterol (HDL-C) concentrations. We sought to assess if these associations could be detected in adolescents.

Methods: Thirty-nine polymorphisms in *NR1H3*, *ABCA1*, *APOE*, *CETP*, *PLTP* and *LPL* were analysed in the HELENA study ($n = 1144$ European adolescents).

Results: The minor alleles of rs11039155 in *NR1H3*, rs2575879 in *ABCA1*, rs708272, rs17231506 and rs5882 in *CETP* and rs328 in *LPL* were associated with higher serum HDL-C concentrations ($p \leq 0.0012$). The minor alleles of rs12221497 in *NR1H3*, rs1800978 in *ABCA1* and the *APOE* $\epsilon 4$ allele were associated with lower HDL-C concentrations ($p \leq 0.01$). The combined set of associated polymorphisms accounted for $\sim 6.6\%$ of the variance in HDL-C.

Conclusion: We report for the first time that polymorphisms in *NR1H3* and its target genes *ABCA1*, *APOE*, *CETP* and *LPL* contribute to the genetic variance for HDL-C concentrations in adolescence.

© 2011 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Hypercholesterolemia and low serum HDL-cholesterol (HDL-C) concentrations are risk factors for cardiovascular diseases. A low HDL-C concentration is the most common lipoprotein abnormality in men with coronary artery disease (CAD) [1]. Atherosclerosis starts very early in childhood and progresses from fatty streaks to raised lesions in adolescence and young adulthood [2]. Understanding the knowledge of the genetic determinants of HDL-C concentration in childhood

may help to target individuals at risk of CAD at an early age.

Liver X receptors (LXRs) are nuclear receptors that act as cholesterol sensors and control cholesterol homeostasis by regulating the expression of numerous target genes (see [3] for review). LXR β is ubiquitously expressed, whereas LXR α is predominantly expressed in liver, intestine, adipose tissue and macrophages [4]. LXR α is encoded by the *NR1H3* gene located on 11p11.2. Recent studies have shown that single nucleotide polymorphisms (SNPs) in *NR1H3* are associated with serum HDL-C concentrations in adults [5–7]. Recently, a meta-analysis of genome-wide association studies (GWASs) identified 95 loci contributing to inter-individual variations in serum lipid concentrations [8], including the *NR1H3* gene locus which is associated with HDL-C (rs3136441, $p = 3.48 \times 10^{-18}$). Moreover, many SNPs in LXR α 's target genes (such as *LPL* (lipoprotein lipase), *ABCA1* (ATP-binding cassette A1), *CETP* (cholesterol ester transfer protein), *APOE* (Apolipoprotein E)

* Corresponding author at: INSERM UMR744, Institut Pasteur de Lille, 1 rue du Pr. Calmette, BP 245, 59019 LILLE Cedex, France.

Tel.: +33 3 20 87 73 91; fax: +33 3 20 87 78 94.

E-mail address: aline.meirhaeghe-hurez@pasteur-lille.fr (A. Meirhaeghe).

¹ See Appendix A.

Table 1
Significant associations between SNPs in *CETP*, *APOE*, *NR1H3*, *LPL* or *ABCA1* and HDL-C level (mg/dL).

Gene	SNP/haplotype	Genotype (n), mean \pm S.D.			p value	Q value
<i>NR1H3</i>	rs11039155	11 (842), 54.9 \pm 10.5	12 (266), 56.6 \pm 10.9	22 (29), 60.4 \pm 11.4	0.0012	0.012
<i>NR1H3</i>	rs12221497	11 (871), 55.8 \pm 10.5	12 (249), 54.5 \pm 11.0	22 (20), 49.6 \pm 10.4	0.0046	0.029
<i>ABCA1</i>	rs2575879	11 (380), 54.2 \pm 9.7	12 (554), 55.7 \pm 10.9	22 (204), 56.8 \pm 11.5	0.0036	0.028
<i>ABCA1</i>	rs1800978	11 (664), 55.6 \pm 10.6	12 (238), 54.1 \pm 10.5	22 (19), 50.3 \pm 9.2	0.010	0.044
<i>APOE</i>	ϵ	$\epsilon 2^*$ (166), 57.6 \pm 10.6	$\epsilon 3\epsilon 3$ (695), 55.2 \pm 11.0	$\epsilon 3\epsilon 4/\epsilon 4\epsilon 4$ (219), 54.2 \pm 9.3	4.03E–05	5.10E–04
<i>CETP</i>	rs17231506	11 (517), 53.9 \pm 10.1	12 (484), 56.2 \pm 10.9	22 (108), 59.1 \pm 10.5	1.49E–08	5.67E–07
<i>CETP</i>	rs708272	11 (381), 53.7 \pm 10.6	12 (554), 55.7 \pm 10.6	22 (205), 57.8 \pm 10.4	5.53E–07	1.05E–05
<i>CETP</i>	rs5882	11 (491), 54.4 \pm 10.3	12 (511), 56.0 \pm 10.8	22 (138), 56.8 \pm 10.9	0.0060	0.033
<i>LPL</i>	rs328	11 (878), 55.1 \pm 10.4	12 (244), 56.1 \pm 10.0	22 (18), 61.6 \pm 10.0	0.0063	0.030

1: frequent allele; 2: minor allele; $\epsilon 2^*$: $\epsilon 2\epsilon 2$ or $\epsilon 2\epsilon 3$ or $\epsilon 2\epsilon 4$.

Additive general linear models were used. p values were adjusted for age, gender, centre and BMI.

Correction for multiple testing was performed using false discovery rate Q values.

and *PLTP* (phospholipid transfer protein)) are also associated with HDL-C concentrations.

In the present study, we investigated associations between SNPs in *NR1H3* and these five target genes (*ABCA1*, *CETP*, *APOE*, *PLTP*, *LPL*) on one hand and the serum HDL-C concentration on the other in adolescents.

2. Methods

2.1. Subjects

The recruitment and phenotyping of the adolescents in the HELENA cross-sectional study (www.helenastudy.com) have been previously described [9]. Briefly, a total of 3865 adolescents were recruited between 2006 and 2007 in 10 centres in 9 European countries. The protocol was approved by the appropriate ethics review board for each investigating centre. Written, informed consent was obtained from each adolescent and both of his/her parents or legal representatives. Participation in the study was voluntary. One-third of the classes were randomly selected for blood collection ($n = 1155$). Data on BMI were available for 1144 subjects (i.e. the sample in the present study). Physical activity was assessed with an uni-axial accelerometer (Actigraph™ GT1M, Pensacola, FL, USA) during 7 days [10]. Moderate-vigorous physical activity was dichotomized into <60 and ≥ 60 min/day (<http://www.health.gov/PAGuidelines>). Fasting serum triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol were measured on the Dimension RxL clinical chemistry system (Dade Behring, Schwalbach, Germany) using enzymatic methods [11]. Serum apolipoprotein A1 (ApoA1) concentrations were measured in an immunochemical reaction with a BN II analyzer (Dade Behring). DNA was extracted from white blood cells with the Puregene kit (QIAGEN, Courtaboeuf, France) at the Genomic Analysis Laboratory (Institut Pasteur de Lille, Lille, France).

2.2. Single nucleotide polymorphism selection and genotyping

For *NR1H3*, *PLTP* and *LPL*, tagSNPs were selected using the HapMap (Nov08 release) database (with a minor allele frequency (MAF) above 0.10 and tagSNPs with an r^2 value cut-off above 0.8). For *CETP*, *APOE* and *ABCA1*, several candidate SNPs were included on the basis of a literature survey. In total, 44 SNPs (14 in *LPL*, 9 in *ABCA1*, 7 in *CETP*, 6 in *PLTP*, 4 in *APOE* and 3 in *NR1H3*) were genotyped using the Illumina GoldenGate or VeraCode technologies (except for rs11039155, typed by restriction length fragment polymorphism, as previously described [6]). The genotyping success rates are shown in Supplementary Table 1.

2.3. Statistical analysis

Linkage disequilibrium (LD) between SNPs was assessed by calculating the D' and r^2 values using Haploview software [12]. Statistical analyses were performed with SAS software, version 8.02 (SAS Institute Inc., Cary, NC, USA). A chi-squared test was used to compare genotype and allele distributions and to assess deviation from Hardy–Weinberg equilibrium ($p < 0.01$). Multivariate, additive general linear models (GLMs) were used to study the effects of the SNPs on HDL-C. The homogeneity across centres and by gender was tested using an interaction term in the GLM (all $p > 0.05$). We used age, gender, centre and BMI as covariates. Correction for multiple testing was performed using false discovery rate Q values. To evaluate the proportion of HDL-C variance explained, we incorporated all the SNPs associated (from Table 1), age, BMI, gender, centre and physical activity level in a stepwise multivariate regression model. Power calculations were performed in an additive model using Quanto software version 1.2.4 [13] (University of Southern California, LA, USA).

3. Results

In the study, 48% ($n = 549$) were boys. The mean age was 14.7 ± 1.4 yrs, the mean BMI was 21.3 ± 3.8 kg/m² and the mean serum HDL-C concentration was 55.4 ± 10.7 mg/dL.

After genotyping, two SNPs (rs1800775 in *CETP* and rs281 in *LPL*) were eliminated from the analyses, as there was significant deviation from Hardy–Weinberg equilibrium ($p = 0.00008$ and $p = 0.0002$, respectively) (Supplementary Table 1). We assessed the linkage disequilibrium (LD) pattern for the SNPs in each gene (Supplementary Figure 1). In *CETP*, rs708272 and rs7205804 were in LD ($r^2 = 0.88$) and rs708272 was used as a proxy for rs7205804 in the statistical analyses. Likewise, rs2246293 and rs2422493 in *ABCA1* were perfect proxies ($r^2 = 0.98$). Hence, we ultimately assessed 39 SNPs for association with HDL-C. As usual, rs429358 and rs7412 in *APOE* define three haplotypes, corresponding to the *APOE* $\epsilon 2$, $\epsilon 3$ and $\epsilon 4$ isoforms.

We examined associations between the 39 SNPs and the serum HDL-C concentration (Supplementary Figure 2). Only false discovery rate Q values below 0.05 were considered to be significant. None of the *PLTP* SNPs was significantly associated with the HDL-C concentration (Supplementary Table 2). In contrast, two SNPs in *NR1H3* (rs11039155 and rs12221497) were significantly associated with HDL-C concentration (nominal $p = 0.012$ and 0.0046, respectively) (Table 1). Similarly, seven SNPs in *ABCA1*, *APOE*, *CETP* or *LPL* were significantly associated with HDL-C concentration (Table 1), with the strongest associations being observed for *CETP* (nominal $p = 1.49 \times 10^{-8}$ and 5.53×10^{-7}) and *APOE* (nominal $p = 4.03 \times 10^{-5}$). As physical activity is an important modulator of HDL-C concentration, at least in adults, we further adjusted the




Fig. 1. The proportion of adjusted variance (%) in HDL-C explained by the clinical characteristics of subjects (dark grey boxes) and the SNPs (light grey boxes) in the HELENA study. Age, BMI, gender, centre, physical activity level and the nine SNPs significantly associated with the HDL-C concentration (from Table 1) were included in a stepwise regression analysis. In addition to BMI and gender, six SNPs (rs12221497 and rs11039155 in *NR1H3*, rs1800978 in *ABCA1*, ϵ in *APOE* and rs17231506 and rs5882 in *CETP*) were retained as significant variables at $p < 0.05$ in the model.

analyses for physical activity level and observed that the associations persisted ($9.30 \times 10^{-7} < \text{nominal } p < 0.012$ for these nine SNPs), meaning that they were independent of physical activity level.

We next sought to determine the extent to which these alleles explained the observed inter-individual variability in the HDL-C concentration. BMI and gender explained 11.1% of the variance in HDL-C. Six SNPs (rs12221497 and rs11039155 in *NR1H3*, rs1800978 in *ABCA1*, ϵ in *APOE* and rs17231506 and rs5882 in *CETP*) accounted for 6.6% of the variance in HDL-C, with half of that (3.3%) being due to *CETP* alone (Fig. 1).

To note, among the 39 SNPs, only the *APOE* ϵ polymorphism was significantly associated with ApoA1 concentrations (1.54 ± 0.21 g/L for $\epsilon 2^+$ carriers ($n = 166$), 1.51 ± 0.23 g/L for $\epsilon 3\epsilon 3$ ($n = 669$) and 1.47 ± 0.20 g/L for $\epsilon 3\epsilon 4/\epsilon 4\epsilon 4$ individuals ($n = 215$), nominal $p = 8.41 \times 10^{-5}$ – corrected Q value = 0.0032) (data not shown).

4. Discussion

In the present study, we analysed associations between 39 SNPs in *NR1H3* and five LXR α target genes with the serum HDL-C concentration in European adolescents. We detected significant associations between 2 SNPs in *NR1H3* (rs12221497 and rs11039155) and the serum HDL-C concentration. Five studies [5–8] have now reported an impact of *NR1H3* polymorphisms on HDL-C metabolism. We also detected significant associations between SNPs in *ABCA1*, *LPL*, *APOE* and *CETP* and the HDL-C concentration. The strongest effect was observed for *CETP* ($\sim +2$ mg/dL). These positive associations have already been described in several GWASs or meta-analyses in adult samples (rs3136441 in *LRP4/NR1H3*, rs1883025 in *ABCA1*, rs12678919 in *LPL*, rs4420638 in *APOE* and rs3764261 in *CETP*) [8]. The present results extend these observations to adolescents.

We did not find any association between *PLTP* SNPs and the HDL-C concentration, despite studying rs6065904, a SNP known to modulate serum PLTP activity [14]. The HELENA study has enough statistical power ($>80\%$, at $p < 0.0013$ (0.05 divided by 39 SNPs)) to detect an effect size of 3.0/1.8 mg/dL of HDL-C for a MAF of 0.10/0.49, respectively. In GWASs with adult samples, the effect sizes of the SNPs associated with HDL-C are similar for *PLTP*, *ABCA1* and *APOE* (~ 1 mg/dL) [8]. Therefore, the absence of a significant association of *PLTP* SNPs with HDL-C in our study could be explained by a lower effect for SNPs in *PLTP* than for the other genes in adolescents – in which case, our study would be underpowered. Concerning ApoA1 concentrations, the *APOE* ϵ polymorphism was the only SNP significantly associated in our study. In adults, the effect sizes of the SNPs associated with ApoA1 concentrations range from -1.70 to $+4.10$ [15]. Again, the SNPs might have a lower effect in adolescents than in adults when considering ApoA1 concentrations.

Our study had several advantages and limitations. We analysed for the first time 39 SNPs in 6 different genes in a relatively large population sample of adolescents. The reverse side is that due to the large number of SNPs tested, we had to correct the data for multiple testing and lost weaker associations. A major limit is that our study lacked a replication sample to confirm the data. However, as other studies conducted in adults do show that these SNPs (or proxies) are associated with HDL-C, we are reasonably confident that our data are not false positives. Still, a larger population sample of adolescents would allow detecting weaker associations and help unravelling the genetic determinants of HDL-C concentration at an early age.

In conclusion, if replicated, our results suggest that genetic variability of *NR1H3* and its target genes modulates HDL-C concentration in adolescents.

Acknowledgements

Dr. Luc Dauchet is acknowledged for his help with statistical analyses. The HELENA study received funding from the European Union's Sixth RTD Framework Programme (contract FOOD-CT-2005-007034). The content of this article only reflects the authors' views and the other HELENA study members are not responsible for it. The European Union is not liable for any use that may be made of the information contained therein. The writing group takes sole responsibility for the content of this article.

Appendix A. HELENA Study Group

Co-ordinator: Luis A. Moreno.

Core Group members: Luis A. Moreno, Frédéric Gottrand, Stefaan De Henauw, Marcela González-Gross, Chantal Gilbert.

Steering Committee: Anthony Kafatos (President), Luis A. Moreno, Christian Libersa, Stefaan De Henauw, Sara Castelló, Frédéric Gottrand, Mathilde Kersting, Michael Sjöström, Dénes Molnár, Marcela González-Gross, Jean Dallongeville, Chantal Gilbert, Gunnar Hall, Lea Maes, Luca Scalfi.

Project Manager: Pilar Meléndez.

1. Universidad de Zaragoza (Spain)

Luis A. Moreno, Jesús Fleta, José A. Casajús, Gerardo Rodríguez, Concepción Tomás, María I. Mesana, Germán Vicente-Rodríguez, Adoración Villarroya, Carlos M. Gil, Ignacio Ara, Juan Revenga, Carmen Lachen, Juan Fernández Alvira, Gloria Bueno, Aurora Lázaro, Olga Bueno, Juan F. León, Jesús M^a Garagorri, Manuel Bueno, Juan Pablo Rey López, Iris Iglesia, Paula Velasco, Silvia Bel, Luis A. Gracia Marco, Theodora Mouratidou.

2. Consejo Superior de Investigaciones Científicas (Spain)

Ascensión Marcos, Julia Wärnberg, Esther Nova, Sonia Gómez, Ligia Esperanza Díaz, Javier Romeo, Ana Veses, Belén Zapatera, Tamara Pozo, David Martínez.

3. Université de Lille 2 (France)

Laurent Beghin, Christian Libersa, Frédéric Gottrand, Catalina Iliescu, Juliana Von Berlepsch.

4. Research Institute of Child Nutrition Dortmund, Rheinische Friedrich-Wilhelms-Universität Bonn (Germany)

Mathilde Kersting, Wolfgang Sichert-Hellert, Ellen Koepen.

5. Pécsi Tudományegyetem (University of Pécs) (Hungary)

Dénes Molnár, Eva Erhardt, Katalin Csernus, Katalin Török, Szilvia Bokor, Mrs. Angster, Enikő Nagy, Orsolya Kovács, Judit Répasi.

6. University of Crete School of Medicine (Greece)

Anthony Kafatos, Caroline Codrington, María Plada, Angeliki Papadaki, Katerina Sarri, Anna Viskadourou, Christos Hatzis, Michael Kiriakakis, George Tsimbinos, Constantine Vardavas, Manolis Sbokos, Eva Protoyarakis, Maria Fasoulaki.

7. Institut für Ernährungs- und Lebensmittelwissenschaften–Ernährungsphysiologie. Rheinische Friedrich Wilhelms Universität (Germany)

Peter Stehle, Klaus Pietrzik, Marcela González-Gross, Christina Breidenassel, Andre Spinneker, Jasmin Al-Tahan, Miriam Segoviano, Anke Berchtold, Christine Bierschbach, Erika Blatzheim, Adelheid Schuch, Petra Pickert.

8. University of Granada (Spain)

Manuel J. Castillo, Ángel Gutiérrez, Francisco B Ortega, Jonatan R Ruiz, Enrique G Artero, Vanesa España, David Jiménez-Pavón, Palma Chillón, Cristóbal Sánchez-Muñoz, Magdalena Cuenca.

9. Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione (Italy)

Davide Arcella, Elena Azzini, Emma Barrison, Noemi Bevilacqua, Pasquale Buonocore, Giovina Catasta, Laura Censi, Donatella Ciarapica, Paola D'Acapito, Marika Ferrari, Myriam Galfo, Cinzia Le Donne, Catherine Leclercq, Giuseppe Maiani, Beatrice Mauro, Lorenza Mistura, Antonella Pasquali, Raffaella Piccinelli, Angela Polito, Raffaella Spada, Stefania Sette, Maria Zaccaria.

10. University of Napoli "Federico II" Dept of Food Science (Italy)

Luca Scalfi, Paola Vitaglione, Concetta Montagnese.

11. Ghent University (Belgium)

Ilse De Bourdeaudhuij, Stefaan De Henauw, Tineke De Vriendt, Lea Maes, Christophe Matthys, Carine Vereecken, Mieke de Maeyer, Charlene Ottevaere, Inge Huybrechts.

12. Medical University of Vienna (Austria)

Kurt Widhalm, Katharina Phillipp, Sabine Dietrich, Birgit Kubelka, Marion Boriss-Riedl.

13. Harokopio University (Greece)

Yannis Manios, Eva Grammatikaki, Zoi Bouloubasi, Tina Louisa Cook, Sofia Eleutheriou, Orsalia Consta, George Moschonis, Ioanna Katsaroli, George Kraniou, Stalo Papoutsou, Despoina Keke, Ioanna Petraki, Elena Bellou, Sofia Tanagra, Kostalena Kallianoti, Dionysia Argyropoulou, Katerina Kondaki, Stamatoula Tsirikika, Christos Karaiskos.

14. Institut Pasteur de Lille (France)

Jean Dallongeville, Aline Meirhaeghe.

15. Karolinska Institutet (Sweden)

Michael Sjöström, Jonatan R Ruiz, Francisco B. Ortega, María Hagströmer, Anita Hurtig Wennlöf, Lena Hallström, Emma Patterson, Lydia Kwak, Julia Wärnberg, Nico Rizzo.

16. Asociación de Investigación de la Industria Agroalimentaria (Spain)

Jackie Sánchez-Molero, Sara Castelló, Elena Picó, Maite Navarro, Blanca Viadel, José Enrique Carreres, Gema Merino, Rosa Sanjuán, María Lorente, María José Sánchez.

17. Campden BRI (United Kingdom)

Chantal Gilbert, Sarah Thomas, Elaine Allchurch, Peter Burgess.

18. SIK - Institutet foer Livsmedel och Bioteknik (Sweden)

Gunnar Hall, Annika Astrom, Anna Sverkén, Agneta Broberg.

19. Meurice Recherche & Development asbl (Belgium)

Annick Masson, Claire Lehoux, Pascal Brabant, Philippe Pate, Laurence Fontaine.

20. Campden & Chorleywood Food Development Institute (Hungary)

Andras Sebok, Tunde Kuti, Adrienn Hegyi.

21. Productos Aditivos SA (Spain)

Cristina Maldonado, Ana Llorente.

22. Cárnicas Serrano SL (Spain)

Emilio García.

23. Cederroth International AB (Sweden)

Holger von Fircks, Marianne Lilja Hallberg, Maria Messerer.

24. Lantmännen Food R&D (Sweden)

Mats Larsson, Helena Fredriksson, Viola Adamsson, Ingmar Börjesson.

25. European Food Information Council (Belgium)

Laura Fernández, Laura Smillie, Josephine Wills.

26. Universidad Politécnica de Madrid (Spain)

Marcela González-Gross, Jara Valtueña, David Jiménez-Pavón, Ulrike Albers, Raquel Pedrero, Agustín Meléndez, Pedro J. Benito, Juan José Gómez Lorente, David Cañada, Alejandro Urzanqui, Rosa María Torres, Paloma Navarro.

Appendix B. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.atherosclerosis.2011.01.031.

References

- [1] Kwiterovich Jr PO. The antiatherogenic role of high-density lipoprotein cholesterol. *Am J Cardiol* 1998;82:13Q–21Q.
- [2] Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation* 2002;106:143–60.
- [3] Zhao C, Dahlman-Wright K. Liver X receptor in cholesterol metabolism. *J Endocrinol* 2010;204:233–40.
- [4] Willy PJ, Umesono K, Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev* 1995;9:1033–45.
- [5] Robitaille J, Houde A, Lemieux S, et al. The lipoprotein/lipid profile is modulated by a gene-diet interaction effect between polymorphisms in the liver X receptor-alpha and dietary cholesterol intake in French-Canadians. *Br J Nutr* 2007;97:11–8.
- [6] Legry V, Cotel D, Ferrieres J, et al. Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. *Int J Obes (Lond)* 2008;32:421–8.
- [7] Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet* 2009;41:35–46.
- [8] Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 2010;466:707–13.
- [9] Moreno LA, de Henauw S, Gonzalez-Gross M, et al. Design and implementation of the Healthy Lifestyle in Europe by Nutrition in Adolescence Cross-Sectional Study. *Int J Obes (Lond)* 2008;32(Suppl 5):S4–11.
- [10] Ruiz JR, Labayan I, Ortega FB, et al. Attenuation of the effect of the FTO rs9939609 polymorphism on total and central body fat by physical activity in adolescents: the HELENA study. *Arch Pediatr Adolesc Med* 2010;164:328–33.
- [11] Gonzalez-Gross M, Breidenassel C, Gomez-Martinez S, et al. Sampling and processing of fresh blood samples within a European multicenter nutritional study: evaluation of biomarker stability during transport and storage. *Int J Obes (Lond)* 2008;32(Suppl5):S66–75.
- [12] Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–5.
- [13] Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. <http://hydra.usc.edu/gxe>; 2006.
- [14] Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. *Circulation* 2010;122:470–7.
- [15] Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. *PLoS Genet* 2009;5:e1000730.